Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Thymosin Alpha-1
Also known as: Ta1, Zadaxin, Thymalfasin
Thymosin Alpha-1 is a 28-amino acid peptide originally isolated from thymic tissue. It is an approved drug in over 35 countries (as Zadaxin) for hepatitis B and C treatment and as an immune adjuvant. It has the most clinical evidence of any peptide in this underground category, with multiple randomized controlled trials supporting immune-modulating effects.
Risk Level
Low RiskDifficulty
Intermediate| CAS Number | 62304-98-7 |
| Molecular Formula | C129H215N33O55 |
| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Enhances dendritic cell maturation, increases T-cell and NK cell activity, promotes Th1 cytokine production, and modulates toll-like receptor signaling. Acts as an immune system modulator rather than a simple stimulant, restoring balance in both immunodeficient and hyperinflammatory states.
Dosing Research
Clinical dosing: 1.6 mg subcutaneously twice weekly. Underground protocols often mirror this. Some protocols use daily dosing for acute immune challenges. Typical cycle lengths range from 4 weeks to ongoing maintenance.
Side Effects & Risks
Well-tolerated in clinical trials with a safety profile comparable to placebo. Occasional injection site reactions and rare reports of mild fatigue. Considered one of the safest peptides in this category based on available clinical data.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.